Clinical Trial Update: Dose Escalation Trial of Tefinostat for Cancer Associated Inflamation in Hepatocellular Carcinoma (HCC) [Phase 1, Phase 2]

View source ↗

Summary

A dose-escalation trial of tefinostat for cancer-associated inflammation in hepatocellular carcinoma is described (Phase 1/2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• tefinostat (tefinostat)

Snippet

Sponsor: Queen Mary University of London | Conditions: Hepatocellular Carcinoma | Phase 1, Phase 2 | Status: UNKNOWN